Department of Oncology, Faculty of Medicine and Dentistry, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada.
Cell Cycle. 2013 Aug 15;12(16):2675-83. doi: 10.4161/cc.25795. Epub 2013 Jul 29.
Polycomb protein histone methyltransferase, enhancer of Zeste homolog 2 (EZH2), is frequently overexpressed in human malignancy and is implicated in cancer cell proliferation and invasion. However, it is largely unknown whether EZH2 has a role in modulating the DNA damage response. Here, we show that polycomb repressive complex 2 (PRC2) is recruited to sites of DNA damage. This recruitment is independent of histone 2A variant X (H2AX) and the PI-3-related kinases ATM and DNA-PKcs. We establish that PARP activity is required for retaining PRC2 at sites of DNA damage. Furthermore, depletion of EZH2 in cells decreases the efficiency of DSB repair and increases sensitivity of cells to gamma-irradiation. These data unravel a crucial role of PRC2 in determining cancer cellular sensitivity following DNA damage and suggest that therapeutic targeting of EZH2 activity might serve as a strategy for improving conventional chemotherapy in a given malignancy.
多梳蛋白组蛋白甲基转移酶,EZH2 同源物(EZH2)在人类恶性肿瘤中经常过度表达,并与癌细胞增殖和侵袭有关。然而,EZH2 是否在调节 DNA 损伤反应中起作用在很大程度上尚不清楚。在这里,我们表明多梳抑制复合物 2(PRC2)被募集到 DNA 损伤部位。这种募集与组蛋白 2A 变体 X(H2AX)和 PI-3 相关激酶 ATM 和 DNA-PKcs 无关。我们确定 PARP 活性对于将 PRC2 保留在 DNA 损伤部位是必需的。此外,细胞中 EZH2 的耗竭会降低 DSB 修复的效率,并增加细胞对 γ 辐射的敏感性。这些数据揭示了 PRC2 在决定 DNA 损伤后癌症细胞敏感性方面的关键作用,并表明靶向 EZH2 活性的治疗可能成为改善特定恶性肿瘤中常规化疗的策略。